|
시장보고서
상품코드
2102464
포도막 종양 시장 규모, 점유율 및 성장 분석 : 질환 유형별, 진단 방법별, 치료법별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Uveal Neoplasms Market Size, Share, and Growth Analysis, By Disease Type (Uveal Melanoma, Uveal Lymphoma), By Diagnosis, By Treatment Type, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 포도막 종양 시장 규모는 2024년에 10억 5,000만 달러로 평가되며, 2025년 11억 달러에서 2033년까지 109억 1,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 5.1%로 성장할 것으로 전망되고 있습니다.
전 세계 포도막 종양 시장은 주로 포도막 흑색종 및 그 전이성 병변과 같은 안구 악성 종양을 치료하기 위한 진단법, 치료법 및 수술용 기기를 포괄합니다. 이러한 질환에 수반되는 높은 사망률과 이용 가능한 치료 옵션의 제한으로 인해 연구개발에 대한 투자가 급증하고 있습니다. 고령화에 따른 포도막 흑색종 발생률 증가와 안구 영상 진단 선별 기술의 향상을 주요 요인으로 하여, 시장은 기존의 안구 적출술에서 광자를 이용한 근접 방사선 치료나 체크포인트 억제제 등 첨단 치료법으로 전환되고 있습니다. 표적 치료제나 초맥락막 임플란트와 같은 최소 침습 투여 시스템 같은 혁신 기술이 추가적인 성장을 지원하고 있습니다. 이러한 임상적 진보, 보험 적용 승인, 그리고 제조사의 활동 확대라는 지속적인 선순환이 기존 시장과 신흥 시장 모두에서 환자의 접근성 향상과 수익 확대를 촉진하고 있습니다.
전 세계 포도막 종양 시장의 성장 요인
분자 표적 치료제의 등장으로 치료 가능성이 대폭 확대됨에 따라 의료 종사자들은 기존의 방사선 치료보다 정밀 의학을 우선시하고 있습니다. 이러한 전환으로 인해 환자의 예후가 개선되고, 치료 전략에 대한 신뢰도가 높아지며, 특수 약물전달 시스템에 대한 수요가 증가하고 있습니다. 의료 전문가들이 임상 시험 결과 및 관련 안전성 프로파일에 대해 더 잘 이해하게 됨에 따라 이러한 혁신적인 약물을 일상적인 의료 실무에 도입하려는 경향이 강해지고 있으며, 그 결과 처방률 상승과 지속적인 연구 투자를 통해 시장 성장이 촉진되고 있습니다. 또한 제약사와 학술기관 간의 협력은 치료 옵션의 견고한 파이프라인을 유지하는 데 있으며, 매우 중요한 역할을 하고 있습니다.
전 세계 포도막종 시장의 제약 요인
전 세계 포도막종 시장은 이 희귀 질환을 대상으로 한 치료법의 보험 급여와 관련된 불확실성으로 인해 큰 과제에 직면해 있습니다. 의료 경제에 관한 데이터가 제한적이기 때문에 보험사는 보험 적용 승인에 엄격한 기준을 적용하는 경우가 많으며, 특히 환급 절차가 불분명한 경우 병원이나 임상의가 고비용 치료법의 도입에 소극적일 가능성이 있습니다. 이러한 재정적 신중함은 혁신적인 치료법의 활용 부족으로 이어져 환자의 접근성을 제한하고 처방률 향상을 저해하고 있습니다. 또한 보험 적용에 대한 우려는 제약사가 틈새 치료법 개발에 투자하려는 의지를 약화시켜, 궁극적으로 시장 성장을 정체시키고 연구 자금이 수익성이 더 높은 종양학 분야로 유출될 가능성도 있습니다.
전 세계 포도막 종양 시장 동향
전 세계 포도막 종양 시장에서는 치료 선택의 정확도를 높이는 분자 프로파일링의 발전에 힘입어, 맞춤형 치료로의 큰 전환이 나타나고 있습니다. 이러한 추세는 특정 종양 유전자 경로에 맞춘 표적 치료제 개발을 촉진하고, 기존의 방사선 치료나 광범위한 화학요법에 대한 의존도를 낮추고 있습니다. 제약사들이 바이오마커 기반 의약품 개발을 중시하는 한편, 학술기관들도 정밀 의학의 임상 시험을 확대하고 있으며, 이러한 시너지가 발생하여 맞춤형 치료 프로토콜의 도입을 가속화하고 있습니다. 이러한 변화하는 상황은 환자의 예후 개선, 반응률 향상 및 삶의 질 향상을 목표로 하고 있으며, 전 세계 포도막종 치료 분야에서 보다 전문적이고 효과적인 치료법으로의 강력한 움직임을 반영하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 포도막 종양 시장 규모 : 질환 유형별
세계의 포도막 종양 시장 규모 : 진단별
세계의 포도막 종양 시장 규모 : 치료 유형별
세계의 포도막 종양 시장 규모 : 최종사용자별
세계의 포도막 종양 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.08.05Global Uveal Neoplasms Market size was valued at USD 1.05 Billion in 2024 and is poised to grow from USD 1.1 Billion in 2025 to USD 10.91 Billion by 2033, growing at a CAGR of 5.1% during the forecast period (2026-2033).
The global uveal neoplasms market encompasses diagnostics, therapeutic solutions, and surgical devices for treating ocular malignancies, primarily uveal melanoma and its metastatic variations. Due to the high mortality rates associated with these conditions and the limited treatment options available, there has been a surge in research and development investments. The market has transformed from traditional enucleation methods to advanced therapies, including photon-based brachytherapy and checkpoint inhibitors, driven largely by the rising incidence of uveal melanoma in aging populations and enhanced ocular imaging screening. Innovations like targeted agents and micro-invasion delivery systems, such as suprachoroidal implants, are further propelling growth. This ongoing cycle of clinical advancements, reimbursement approvals, and increased manufacturer activity is fostering patient access and revenue expansion in both established and emerging markets.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Uveal Neoplasms market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Uveal Neoplasms Market Segments Analysis
Global uveal neoplasms market is segmented by by disease type, by diagnosis, by treatment type, by end user and region. Based on by disease type, the market is segmented into Uveal Melanoma, Uveal Lymphoma, Iris Neoplasms, Ciliary Body Neoplasms, Choroidal Neoplasms and Others. Based on by diagnosis, the market is segmented into Ophthalmic Examination, Imaging Techniques, Biopsy & Histopathology and Molecular & Genetic Testing. Based on by treatment type, the market is segmented into Surgery, Radiation Therapy, Laser Therapy, Systemic Therapy and Combination Therapy. Based on by end user, the market is segmented into Hospitals, Specialty Ophthalmology Clinics, Cancer Centers, Ambulatory Surgical Centers and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Uveal Neoplasms Market
The emergence of molecularly targeted therapeutics has significantly broadened treatment possibilities, prompting healthcare providers to favor precision medicine over traditional radiation therapies. This transition is enhancing patient outcomes, fostering greater confidence in treatment strategies, and creating a heightened demand for specialized drug delivery systems. As practitioners become more acquainted with clinical trial findings and the associated safety profiles, there is a growing inclination to integrate these innovative agents into everyday medical practice, thus fueling market growth through higher prescription rates and ongoing research investments. Furthermore, partnerships between pharmaceutical companies and academic institutions play a crucial role in maintaining a robust pipeline of therapeutic options.
Restraints in the Global Uveal Neoplasms Market
The Global Uveal Neoplasms market faces significant challenges due to the uncertainty surrounding reimbursements for treatments targeting this rare condition. Limited health-economics data often prompt payers to impose strict criteria for coverage approval, which can lead hospitals and clinicians to be reluctant in adopting high-cost interventions, particularly when reimbursement processes are unclear. This fiscal caution results in the underutilization of innovative therapies, restricting patient access and hindering prescription rates. Additionally, the apprehension regarding reimbursement diminishes incentives for manufacturers to invest in the development of niche treatments, ultimately stalling market growth and potentially diverting research funding toward more lucrative oncology sectors.
Market Trends of the Global Uveal Neoplasms Market
The Global Uveal Neoplasms market is witnessing a significant shift towards personalized therapy, propelled by advancements in molecular profiling that enhance the precision of treatment options. This trend fosters the development of targeted agents tailored to specific oncogenic pathways, reducing dependence on traditional radiation and broad-spectrum chemotherapy. As pharmaceutical companies emphasize biomarker-guided drug development, academic institutions are expanding precision medicine trials, leading to a synergistic collaboration that accelerates the adoption of individualized treatment protocols. This evolving landscape aims to enhance patient outcomes, improve response rates, and elevate quality of life, reflecting a robust movement towards more specialized and effective therapies in uveal neoplasms worldwide.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Uveal Neoplasms Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Uveal Melanoma
- Uveal Lymphoma
- Iris Neoplasms
- Ciliary Body Neoplasms
- Choroidal Neoplasms
- Others
Global Uveal Neoplasms Market Size by Diagnosis & CAGR (2026-2033)
- Market Overview
- Ophthalmic Examination
- Imaging Techniques
- Ocular Ultrasound
- Optical Coherence Tomography (OCT)
- Fundus Photography & Fluorescein Angiography
- MRI & CT Imaging
- Biopsy & Histopathology
- Molecular & Genetic Testing
Global Uveal Neoplasms Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Surgery
- Radiation Therapy
- Laser Therapy
- Systemic Therapy
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Combination Therapy
Global Uveal Neoplasms Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Ophthalmology Clinics
- Cancer Centers
- Ambulatory Surgical Centers
- Academic & Research Institutes
Global Uveal Neoplasms Market Size & CAGR (2026-2033)
- North America (By Disease Type, By Diagnosis, By Treatment Type, By End User)
- US
- Canada
- Europe (By Disease Type, By Diagnosis, By Treatment Type, By End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (By Disease Type, By Diagnosis, By Treatment Type, By End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (By Disease Type, By Diagnosis, By Treatment Type, By End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (By Disease Type, By Diagnosis, By Treatment Type, By End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Immunocore Holdings plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eckert & Ziegler AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Elekta AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Accuray Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aura Biosciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Delcath Systems Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Castle Biosciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IsoAid LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bebig
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Advanced Accelerator Applications
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
(주말 및 공휴일 제외)
